Alyeska Investment Group
IOBT

Alyeska Investment Group’s IO Biotech IOBT Stock Holding History

Alyeska Investment Group’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-987,654
Closed -$1.18M – 590
2023
Q3 		$1.39M Buy
+987,654
New +$1.74M 0.01% 407

Other funds holding IOBT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Alyeska Investment Group's IOBT Position: Q4 2023 in Review

Alyeska Investment Group sold out of IO Biotech (IOBT) in Q4 2023, closing a stake of 987,654 shares — an estimated $1.18M sold.

Alyeska Investment Group first reported a position in IOBT in Q3 2023 and held it in 1 quarter. The position peaked at $1.39M in Q3 2023. 18 funds tracked by Wall St. Rank hold IOBT as of Q4 2023.

  • Alyeska Investment Group reported no remaining IO Biotech position as of Q4 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 987,654 IO Biotech shares in Q4 2023, an estimated $1.18M.
  • Alyeska Investment Group first reported a position in IO Biotech in Q3 2023 and held it in 1 quarter.
  • Alyeska Investment Group's IO Biotech position peaked at $1.39M in Q3 2023.
  • 18 funds tracked by Wall St. Rank held IO Biotech as of Q4 2023.

Based on Alyeska Investment Group's 13F filing for Q4 2023, filed 14 Feb 2024.